Blueteq Folder
- 29/01/2026
- dabrafenib and trametinib
-
-
- 29/01/2026
- crizotinib
-
-
- 29/01/2026
- avelumab (Bavencio®)
-
-
-
Oncology
Cancer
- 29/01/2026
- avelumab (Bavencio®)
-
-
-
Oncology
Cancer
- 29/01/2026
- avelumab (Bavencio®)
-
-
- 29/01/2026
- pirfenidone
-
-
-
Respiratory
- 29/01/2026
- nintedanib
-
-
-
Respiratory
- 29/01/2026
- nintedanib
-
-
-
Respiratory
- 29/01/2026
- nintedanib
-
-
-
Respiratory
- 15/01/2026
- Wales Severe Asthma Form: BIOLOGIC INITIATION FORM
-
-
-
-Benralizumab (Fasenra) SC
-Dupilumab (Dupixent) SC
-Mepolizumab (Nucala) SC
-Omalizumab (Xolair) SC
-Tezepelumab (Tezspire) SC
-Reslizumab (Cinqaero) IV
-Omalizumab Biosimilar (Omlyclo) SC
- 15/01/2026
- Wales Severe Asthma Form: ANNUAL REVIEW FORM
-
-
-
-Benralizumab (Fasenra) SC
-Dupilumab (Dupixent) SC
-Mepolizumab (Nucala) SC
-Omalizumab (Xolair) SC
-Tezepelumab (Tezspire) SC
-Reslizumab (Cinqaero) IV
-Omalizumab Biosimilar (Omlyclo) SC
- 15/01/2026
- Wales Severe Asthma Form: SWITCH FORM
-
-
-
-Benralizumab (Fasenra) SC
-Dupilumab (Dupixent) SC
-Mepolizumab (Nucala) SC
-Omalizumab (Xolair) SC
-Tezepelumab (Tezspire) SC
-Reslizumab (Cinqaero) IV
-Omalizumab Biosimilar (Omlyclo) SC
- 15/01/2026
- Biosimilar omalizumab
-
-
- 15/01/2026
- omalizumab (Xolair®)
-
-
- 15/01/2026
- benralizumab (Fasenra®)
-
-
- 15/01/2026
- dupilumab (Dupixent®)
-
-
- 15/01/2026
- reslizumab (Cinqaero®)
-
-
- 15/01/2026
- mepolizumab (Nucala®)
-
-
- 29/12/2025
- tocilizumab (Roactemra®)
-
-
- 15/01/2026
- tezepelumab (Tezspire®)
-
-